Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 51, Issue 1, 2008, Pages 34-41

  Smith, Malcolm A ^a   Morton, Christopher L ^b   Phelps, Doris A ^b   Kolb, E Anders ^c   Lock, Richard ^d   Carol, Hernan ^d   Reynolds, C Patrick ^e   Maris, John M ^f   Keir, Stephen T ^g   Wu, Jianrong ^b   Houghton, Peter J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alvespimycin; Developmental therapeutics; Preclinical testing

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ALVESPIMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; KOS 1022;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GENE INDUCTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; STRESS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 44149091042     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21508     Document Type: Article

References (40)

1. Cullinan SB, Whitesell L. Heat shock protein 90: A unique chemotherapeutic target. Semin Oncol 2006;33:457-465.
2. Gorre ME, Ellwood-Yen K, Chiosis G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002;100: 3041-3044.
3. Bonvini P, Gastaldi T, Falini B, et al. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: Down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 2002;62:1559-1566.
4. Basso AD, Solit DB, Munster PN, et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress H ER2. Oncogene 2002;21:1159-1166.
5. Solit DB, Rosen N. Hsp90: A novel target for cancer therapy. Curr Top Med Chem 2006;6:1205-1214.
6. da Rocha Dias S, Friedlos F, Light Y, et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17- demethoxygeldanamycin. Cancer Res 2005;65: 10686-10691.
7. Torres EM, Sokolsky T, Tucker CM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007;317:916-924.
8. Kaur G, Belotti D, Burger AM, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: An orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10:4813-4821.
9. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-125.
10. Yao Q, Nishiuchi R, Li Q, et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483-4493.
11. Calabrese C, Frank A, Maclean K, et al. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM. J Biol Chem 2003;278:24951-24959.
12. Kim S, Kang J, Hu W, et al. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003; 103:352-359.
13. Kang J, Kamal A, Burrows FJ, et al. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 2006;26: 1903-1908.
14. Keshelava N, Frgala T, Krejsa J, et al. DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005; 110:139-153.
15. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:37-45.
16. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
17. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
18. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
19. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
20. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
21. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007;6:1620-1628.
22. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-6093.
23. Houghton PJ, Maris JM, Friedman HS, et al. Evaluation of Bortezomib against childhood tumor models by the Pediatric Preclinical Testing Program (PPTP). Clin Cancer Res 2005;11: Abstr #A96.
24. Houghton PJ, Maris JM, Friedman HS, et al. Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992). Eur J Cancer Suppl 2006;4:98.
25. Smith MA, Maris JM, Keir ST, et al. Pediatric preclinical testing program (PPTP) evaluation of the Bcl-2 inhibitor ABT-263. Proc Annu Meet Am Assoc Cancer Res 2007; Abstr #4951.
26. Eiseman JL, Lan J, Lagattuta TF, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)-ethyl]amino]geldanamycin (17DMAG, NSC 707545) in CB-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32.
27. Murgo AJ, Kummar S, Gardner ER, et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly. J Clin Oncol 2007;25: Abstr #3566.
28. Lancet J, Baer MR, Gojo I, et al. Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies. Blood 2006;108: Abstr #1961.
29. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49:7-19.
30. Egorin MJ, Belani CP, Remick SC, et al. Phase I, pharmacokinetic (PK), & pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17- demethoxygeldanamycin, (17DMAG, NSC 707545) in patients with advanced solid tumors. J Clin Oncol 2006;24: Abstr #3021.
31. Richardson P, Chanan-Khan AA, Lonial S, et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006;108: Abstr #406.
32. Modi S, Stopeck AT, Gordon MS, et al. Phase 1 dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T). Proc Am Assoc Cancer Res 2006;47: Abstr #2919.
33. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-17413.
34. Demetri GD, George S, Morgan JA, et al. Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patients with metastatic GIST: Results of a Phase I Trial of ipi-504, a water-soluble Hsp90 inhibitor. Eur J Cancer Suppl 2006;4:173.
35. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-566.
36. Wetzler M, Earp JC, Brady MT, et al. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity - Pharmacodynamic drug-drug interaction modeling. Clin Cancer Res 2007;13: 2261-2270.
37. Robles AI, Wright MH, Gandhi B, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 2006;12:6547-6556.
38. Camphausen K, Tofilon PJ. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res 2007;13:4326-4330.
39. Bagatell R, Gore L, Egorin M, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-Allylamino-17-demethoxygeldanamycin (17AAG) in children with solid tumors. J Clin Oncol 2006;24: Abstr #9022.
40. Weigel BJ, Blaney SM, Kersey J, et al., A phase I study of 17-AAG in relapsed/refractory pediatric patients with solid tumors: A Children's Oncology Group Study. J Clin Oncol 2006;24: Abstr #9018.